Treatment of Androgen Excess in Adolescent Girls: Ethinylestradiol-Cyproteroneacetate Versus Low-Dose Pioglitazone-Flutamide-Metformin EDITORIAL COMMENT


Por: Ibañez-Toda L, Díaz-Silva M, Sebastiani G, Sánchez-Infantes D, Salvador-Alarcon C, Lopez-Bermejo A and De Zegher, F.

Publicada: 1 abr 2012
Resumen:
Ovarian androgen excess in adolescent girls is considered to be an ovarian disorder of postmenarcheal onset. Accordingly, ovary-silencing therapy usually with an "estro-progestagen" often is initiated in adolescence. Recent evidence linking insulin resistance to adipose tissue excess in adolescent girls with this disorder suggested the use of an alternative therapy aimed at remodeling the body of the girl to lower visceral hepatic adiposity, reducing low-grade inflammation, and improving the adipokine profile. A therapy comprising a low-dose combination of pioglitazone, flutamide, and metformin (PioFluMet) exerted such effects in hyperandrogenic women who were concomitantly receiving an estroprogestagen. This open-labeled, randomized study compared the effects of treatment with ethinyl estradiol-cyproterone acetate (EE-CA) and PioFluMet in adolescent girls with androgen excess and without pregnancy risk. A total of 34 adolescents with hyperinsulinemic androgen excess were randomized to receive EE-CA (n = 17) or PioFluMet (n = 17) for 6 months. Outcome measures assessed included hirsutism and acne scores, androgen excess, fasting insulin, lipid profile, C-reactive protein, high molecular-weight adiponectin, leptin, follistatin, carotid intima-media thickness, body composition (absorptiometry), and abdominal fat partitioning (Magnetic Resonance Imaging). The effects of EE-CA and PioFluMet at 6 months were comparable in attenuating androgen excess, but were divergent for the following markers, pointing to an advantage of low-dose PioFluMet. Opposing effects were found for fasting insulinemia, circulating cholesterol, triglycerides, C-reactive protein, high-molecular-weight adiponectin, leptin, and follistatin, as well as for carotid intima-media thickness, lean mass, and abdominal, visceral, and hepatic fat. These findings show that EE-CA and low-dose PioFluMet are comparable in reducing androgen excess in adolescents without pregnancy risk, but have divergent effects on several markers, suggesting an advantage of PioFluMet. Further studies are needed in large cohorts to determine the long-term safety and efficacy of low-dose PioFluMet.

Filiaciones:
Univ Barcelona, Hosp St Joan de Deu, Dept Gynecol, Barcelona, Spain.
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain.
Dr Josep Trueta Hosp, Dept Pediat, Girona, Spain.
Girona Inst Biomed Res, Girona, Spain.
Univ Louvain, Louvain, Belgium.
Univ Barcelona, Hosp St Joan de Deu, Dept Gynecol, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Dr Josep Trueta Hosp, Dept Pediat, Girona, Spain
Girona Inst Biomed Res, Girona, Spain
Univ Louvain, Louvain, Belgium
ISSN: 00297828





OBSTETRICAL & GYNECOLOGICAL SURVEY
Editorial
LIPPINCOTT WILLIAMS & WILKINS, TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103, Estados Unidos America
Tipo de documento: Editorial Material
Volumen: 67 Número: 4
Páginas: 233-234
WOS Id: 000302793000013

MÉTRICAS